To ask the Secretary of State for Health and Social Care, what treatment options are available to patients with multiple myeloma who have become refractory to previous lines of therapy.
- Daratumumab with bortezomib and dexamethasone (NICE TA573);
- Carfilzomib (NICE TA 457);
- Bortezomib (NICE TA 129); and
- Ixazomib with lenalidomide and dexamethasone (NICE TA505).
For some patients, stem cell transplantation may also be considered, however, the treatment is very intensive and requires a good level of fitness.